Today: 20 May 2026
IBM stock slides nearly 2% in year-end session as profit-taking dents Dow
31 December 2025
1 min read

IBM stock slides nearly 2% in year-end session as profit-taking dents Dow

NEW YORK, December 31, 2025, 3:21 PM ET — Regular session

  • IBM shares fell about 1.8% in afternoon trading, extending a late-December pullback.
  • An amended SEC filing showed a director corrected a prior insider disclosure tied to deferred board fees.
  • Traders are watching thin year-end liquidity and IBM’s next earnings update, slated for late January.

Shares of International Business Machines Corp fell about 1.8% on Wednesday, trading around $296.64 in the afternoon after touching a session low of $295.92. The stock opened near $301.76 and was set for its second straight daily drop as the year winds down.

The move matters because the final sessions of the year often bring thinner trading and sharper swings, especially in high-priced Dow components. With many investors sitting on sizable 2025 gains, even routine portfolio tweaks can hit bellwethers like IBM harder than usual.

U.S. stocks drifted lower on the day, led by a slip in technology shares, as investors used the quiet week to lock in gains. “It’s perfectly fine in any bull market to have moments of cost,” said Giuseppe Sette, co-founder and president of Reflexivity, pointing to profit-taking when liquidity — how easily assets trade without big price moves — is low. Trading volumes have stayed light in the holiday-shortened week, with U.S. markets closed Thursday for New Year’s Day. Reuters

IBM’s decline carried extra weight in the Dow, a price-weighted index where higher-priced stocks move the gauge more than lower-priced ones, regardless of company size. MarketWatch estimated a $1 move in IBM translates to roughly 6 Dow points, amplifying the index impact of an otherwise ordinary pullback.

Even after Wednesday’s dip, IBM has been one of the stronger blue-chip performers this year, up about 39% year to date, which can invite late-year rebalancing.

Company-specific headlines were sparse, leaving the stock to trade largely with the broader tape. In year-end conditions, that can mean outsized moves on modest flows rather than fresh fundamentals.

In regulatory disclosures, an amended Form 4 filed Monday showed IBM director Martha E. Pollack corrected an earlier insider report, saying a prior filing omitted 4.283 “Promised Fee Shares” — deferred board fees linked to IBM stock — due to an administrative error. The filing said the deferred units are paid out after retirement in stock or cash. SEC

Form 4 filings track insiders’ stock-related transactions and amendments typically reflect corrections rather than new buying or selling. They rarely drive day-to-day price action, but investors monitor them for changes in insider exposure.

Looking ahead, the next major scheduled catalyst is IBM’s fourth-quarter earnings report, which the company has listed for January 28, 2026 (a preliminary date). Investors will be watching for updates on software momentum, consulting demand and cash generation as corporate tech budgets reset for 2026.

Before then, traders expect IBM to remain sensitive to broad market positioning and rate expectations, with liquidity conditions likely to dominate into the year-end close. Round-number levels near $300 are also in focus as investors gauge whether the stock stabilizes into the new year.

Stock Market Today

  • Minnesota First State to Ban Prediction Markets, Faces Federal Lawsuit
    May 19, 2026, 9:51 PM EDT. Minnesota has become the first U.S. state to officially ban prediction markets, platforms where users bet on event outcomes. This move follows debates in at least 14 other states on how to regulate these online markets, which blend financial speculation with forecasting. The federal government has filed a lawsuit against Minnesota's new law, challenging its prohibition. Prediction markets are viewed by supporters as effective forecasting tools but face legal scrutiny over gambling concerns. Minnesota's ban marks a significant development in the ongoing regulatory landscape for emerging digital betting and financial products.

Latest articles

Wall Street Hit by Yield Jolt With Nvidia Up Next

Wall Street Hit by Yield Jolt With Nvidia Up Next

20 May 2026
U.S. stock ETFs remained lower late Tuesday after Wall Street’s main indexes fell for a third straight session, pressured by rising Treasury yields and caution ahead of Nvidia’s earnings. The SPDR S&P 500 ETF dropped 0.7% to $733.73. The 10-year Treasury yield hit 4.687%, its highest since January 2025, before easing. Nvidia shares slipped 0.7% after hours, with traders bracing for a major move post-earnings.
Viavi Stock Drops After $500 Million Share Sale Plan — The Debt Move Investors Can’t Ignore

Viavi Stock Drops After $500 Million Share Sale Plan — The Debt Move Investors Can’t Ignore

20 May 2026
Viavi Solutions shares dropped 7.1% in after-hours trading Tuesday after the company announced a $500 million public stock offering aimed at repaying debt. The offering, unveiled just after the Nasdaq close, could add roughly 10.1 million new shares. Viavi plans to use proceeds to pay down a $450 million loan. Total debt would fall to $650 million, according to a preliminary SEC filing.
Analog Devices Shares Rally After $1.5B AI Power Deal Ahead of Earnings

Analog Devices Shares Rally After $1.5B AI Power Deal Ahead of Earnings

20 May 2026
Analog Devices agreed to acquire Empower Semiconductor for $1.5 billion in cash, sending ADI shares up 1.36% to $419.95 in after-hours trading after closing down 1.02%. The deal, approved by both boards, is expected to close in the second half of 2026 pending regulatory review. Empower CEO Tim Phillips will continue to lead integrated voltage regulator work after the merger.
AI stocks today: Nvidia, AMD tick higher as year-end trade turns cautious
Previous Story

AI stocks today: Nvidia, AMD tick higher as year-end trade turns cautious

Outlook Therapeutics stock drops after FDA issues another Lytenava CRL for wet AMD
Next Story

Outlook Therapeutics stock drops after FDA issues another Lytenava CRL for wet AMD

Go toTop